biofil chemicals has scheduled a board meeting for May 30, 2026, to consider and approve the audited financial results for the fourth quarter and financial year ended March 31, 2026. The meeting will be held at the company's registered office located at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.).

Agenda for the Meeting

The primary agenda item for the board meeting is the consideration and approval of the audited financial results for the quarter and year ending March 31, 2026. This includes the review of the Auditor's Report, the Statement of Assets and Liabilities, and the Cash Flow Statement. The board will also consider other routine matters with the permission of the chair.

Trading Window Update

In continuation of an earlier disclosure dated March 24, 2026, the company has informed the exchanges about the trading window closure. Pursuant to the Company's Code of Conduct to regulate, monitor, and report trading in the company's securities by Insiders, the trading window will open 48 hours after the declaration of the audited financial results. This applies to all designated persons, their immediate relatives, and all connected persons covered under the code.

Regulatory Compliance

The company confirmed that the information regarding the meeting and financial results will be submitted in XBRL mode, along with the submission in PDF mode, within the prescribed time limit. The intimation was sent to the Corporate Relationship Departments of both the National Stock Exchange of India Limited and BSE Limited.

Biofil Chemicals and Pharmaceuticals Limited has issued a formal intimation to its shareholders holding shares in physical mode, directing them to mandatorily furnish key compliance-related details. The communication, dated May 05, 2026, was filed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is in alignment with the SEBI Master Circular for Registrars to an Issue and Share Transfer Agents dated February 06, 2026.

Regulatory Background

The intimation has been issued in compliance with SEBI Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 06, 2026. As per the regulatory mandate, all holders of physical securities in listed companies are required to provide specific details to the Registrar and Share Transfer Agent (RTA) of the company. The company has highlighted that this update is essential to ensure seamless communication, compliance with regulatory requirements, and proper credit of dividends, if any, directly to shareholders' bank accounts.

Details Required from Physical Shareholders

Physical shareholders are required to submit the following information to the RTA:

• PAN — Permanent Account Number for identity verification
• Choice of Nomination — via Form SH-13, or cancellation/variation via Form SH-14; shareholders may also opt out via Form ISR-3
• Contact Details — postal address with PIN code and mobile number, registerable via Form ISR-1
• Bank Account Details — bank name, branch name, account number, and IFS code, submittable via Form ISR-1
• Specimen Signature — mandatory for all physical folio holders

Consequences of Non-Compliance

Shareholders whose folios do not have PAN, KYC details, and nomination updated will face the following restrictions:

• They will be eligible to lodge grievances or avail any service request from the RTA only after furnishing PAN, KYC details, and nomination.
• With effect from April 01, 2024, any payment including dividend, interest, or redemption payment in respect of such folios will be made only through electronic mode. An intimation will be sent by the company to the security holder that such payment is due and will be made electronically only upon complying with the stated requirements.

Submission Modes

Shareholders may submit the required documents and details through any one of the following modes:

• In Person Verification (IPV): The authorized person of the RTA shall verify original documents and retain copies with IPV stamping, date, and initials.
• Hard copies: Self-attested and dated copies submitted directly.
• Electronic mode: Submission with e-sign, as elaborated under the applicable SEBI circular.

RTA Contact Details

Shareholders are requested to submit the required details to the company's RTA at the earliest. The contact information for the RTA is provided below:

The relevant forms for nomination and updation of PAN/KYC details are available on the company's website as well as on the RTA's website at www.ankitonline.com . The intimation was signed by Apoorv Jain, Company Secretary and Compliance Officer, on behalf of Biofil Chemicals and Pharmaceuticals Limited.